What is SRTS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SRTS?

P/E (TTM) is n/a and 52-week range is $2.66 to $5.49 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SRTS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SRTS?

The company profile lists revenue (TTM) near $18M, net income (TTM) near $-1.55B, EPS (TTM) near $-0.94 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Sensus Healthcare Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boca Raton, Florida, US, 16.5M shares outstanding, ISIN US81728J1097 when available from company profile and filing metadata.

Sensus Healthcare Inc

$SRTS

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$2.95

-0.67%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 60 full-time employees. The company went IPO on 2016-06-03. The firm is engaged in the development and delivery of non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The firm uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is incorporated into a portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT technology is used to effectively and safely treat oncological and non-oncological skin conditions. The SRT-100 is a photon x-ray low-energy SRT system that provides patients with an alternative to surgery for treating NMSC, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with an SRT-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and comprehensive dosimetry parameters.

Employees

Website

sensushealthcare.com/

IPO

2016-06-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)